Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

Our Discoveries

Photomicrograph of a diffuse large B-cell lymphoma

New insights into the origins of an aggressive form of lymphoma

A new study sheds light on the origin of an aggressive subtype of diffuse large B cell lymphoma (DLBCL). The findings could help researchers develop more targeted therapies for this form of blood cancer.

Bacteria inside lung tumors concentrate within cancer cells

Researchers discovered that tumor-promoting signals are elevated in lung tumor cells with high concentrations of bacteria. These findings support the idea that reducing bacteria in the lungs might be beneficial for patients with lung cancer.

Cytotoxic T cells (red) are shown attacking a squamous cancer cell (white).

Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors

CCR scientists have assembled a library of immune receptors that direct T cells to target cells with mutations in p53, the most commonly mutated gene in human cancers.

Microscopic view of a tissue sample of ductal cell carcinoma from human breast cancer. Image credit: Allan Weissman, M.D., Senior Investigator in the Cancer Innovation Laboratory at CCR, and Kevin Gardner, M.D., Ph.D., Professor of Pathology and Cell Biology at Columbia University.

A protein predicts poor breast cancer survival for women of African descent

CCR and Columbia University researchers have discovered that large amounts of the gp78 protein in breast cancer tumors predict worse outcomes for patients of African ancestry. Their findings provide some new understanding of a significant health disparity in breast cancer.

pattern of DNA methylation in a meningioma tumor

New way to classify meningioma brain tumors suggests potential treatments

Two studies have found a new way to classify meningioma, a type of tumor that forms in the outer covering of the brain. Kenneth Aldape, M.D., Chief and Senior Investigator of the Laboratory of Pathology, speaks about how the new grouping system may help predict whether a patient’s tumor will grow back after treatment and may reveal new treatment possibilities.

Machine learning reveals rules of T cell activation

CCR and McGill University scientists have used machine learning to build models that can predict T cell responses against tumors.

a group of killer T cells (light blue) surround a cancer cell (dark red/black)

Computational model finds signatures of T cell resilience in solid tumors

Evaluating T cell resilience can help researchers predict — and possibly improve — immunotherapy outcomes.

Protein signature in the blood linked to prostate cancer lethality in men of African ancestry

African American men have an increased risk for lethal prostate cancer. CCR researchers have found that an immunity-related protein signature in the blood is more prevalent in men of African ancestry, which may help explain this devastating health disparity.

3D illustration proteins with lymphocytes , T cells or cancer cells

Unique gene expression profiles identify rare T cells that could be effective in cancer immunotherapy

CCR researchers led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, have found unique expression profiles in 50 genes that help identify rare anti-tumor lymphocytes that can be used as personalized immunotherapy in many patients with metastatic solid tumors.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

Breadcrumb

Our Discoveries